(Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline results from the PIK3CA mutant cohort of the Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results